

Salinomycin Induces Autophagic Cell Death in Salinomycin-Sensitive Melanoma Cells through Inhibition of Autophagic Flux

Yajing Liu^{1,4#}, Yinghua Hao^{1,#}, Yuxia Li¹, Yadan Zheng¹, Jiajing Dai¹, Fubo Zhong¹, Wei Wei^{2*}, Zhengyu Fang^{1,3*}

¹Biomedical Research Institute, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China;

²Department of Thyroid and Breast Surgery , Peking University Shenzhen Hospital, Shenzhen, 518036, China;


³Clinical Research Institute, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China;

⁴Department of Medical Genetics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005, China.

#These authors contributed equally to this work.

Supplementary Data


Supplementary Fig.S1




Supplementary Fig.S1: The structural formula of salinomycin.

Supplementary Fig.S2

A




B




Supplementary Fig.S2: Sal had an inhibitory effect on the tumor growth *in vivo*. (A) The body weight curve of five groups during 15 days of treatment. (B) The photo of mice tumor tissues dissected on the 15th day of treatment.

Supplementary Fig.S3



Supplementary Fig.S3: Typical apoptosis morphological features were observed in a few SK-Mel-19 cells. EM image showing chromatin condensation and margination in 1.0µM Sal-treated SK-Mel-19 cell.

Supplementary Fig.S4



Supplementary Fig.S4: There is no correlation between the sensitivity to Sal and the pigmentation of eight melanoma cell lines.

Supplementary Table S1: Detailed information of clinical characteristics of melanoma patients

No.	Gender	Age	Location	Stage	Smoking history	Family history
1	male	51	foot	II	yes	none
2	male	63	neck	I	yes	none

3	male	35	face	I	yes	yes
4	female	59	foot	III	none	none
5	male	62	hand	II	yes	none
6	female	52	arm	II	none	none
7	male	45	back	III	none	yes
8	male	66	foot	IV	yes	none
9	male	39	body	II	yes	none
10	male	54	arm	II	yes	none
11	female	36	face	II	none	none
12	female	38	foot	III	none	none
13	male	62	leg	IV	yes	none
14	male	60	face	I	yes	none
15	female	43	chest	II	none	none
16	male	50	back	III	none	none
17	male	33	hand	II	yes	none
18	female	31	abdomen	II	none	none
19	male	58	neck	I	none	none
20	male	53	hand	II	yes	none
21	male	57	foot	IV	yes	none
22	male	47	finger	I	yes	none
23	female	40	foot	II	none	none
24	female	33	scalp	III	none	yes
25	female	67	leg	IV	none	none
26	male	53	abdomen	II	yes	none
27	male	56	foot	III	none	none
28	female	63	scalp	II	none	none
29	male	40	arm	II	yes	none
30	male	47	foot	III	yes	none
31	male	57	leg	IV	yes	none
32	female	50	foot	II	none	none
33	male	55	chest	II	none	none
34	female	28	leg	III	none	yes
35	male	26	hand	I	none	none
36	male	72	finger	II	yes	none
37	female	41	face	II	none	none
38	male	60	neck	II	yes	none
39	female	37	back	III	none	none
40	male	46	foot	IV	none	yes
41	male	61	foot	II	yes	none
42	male	51	chest	III	yes	none
43	male	48	foot	II	none	none

Supplementary Table S2: Some cell lines that were sensitive to Sal were not sensitive to cisplatin.

Comparison of IC₅₀ of Sal and DDP in eight melanoma cell lines.

Melanoma cell lines	IC ₅₀ of Sal	IC ₅₀ of DDP
M7	8.05	1.57
M8	15.78	8.88
M21	1.38	1.68
M29	3.63	8.91
SK-MEL-1	4.15	5.37
SK-MEL-19	0.82	10.16
SK-MEL-103	4.07	6.95
A375	5.71	11.43

Uncropped Western Blot Images

Figure 2B-Cleaved PARP1




Figure 2B-Cleaved Caspase3




Figure 2B-Caspase9&Cleaved Caspase9&B2M




Figure 2C-Cleaved Caspase3




Figure 2C-B2M




Figure 3A-LC3




Figure 3A-B2M




Figure 3B-Beclin-1




Figure 3B-B2M




Figure 4A-P62&B2M




Figure 4D-Ubiquitin




Figure 4D-B2M




Figure 4E-LC3&B2M




Figure 6B-Bip/GRP78




Figure 6B-IRE1a




Figure 6B-P-PERK




Figure 6B- P-eIF2a




Figure 6B- CHOP & B2M

